Although the disease burden of Respiratory Syncytial Virus (RSV) is significant, no human vaccine exists. Historical clinical trial complications in the 1960s and the lack of understanding concerning RSV viral correlates of protection (CoP) and viable in vitro and in vivo models have delayed RSV vaccine development. The World Health Organization (WHO), PATH, the Bill & Melinda Gates Foundation, and the Respiratory Syncytial Virus Network have been dedicated to RSV research efforts. The new vaccine and monoclonal antibody (mAb) candidates, built upon emerging knowledge, show potential for human vaccine viability by 2025 according to the WHO’s Product Development for Vaccines Advisory Committee (Mazur et al., 2018; Shi et al., 2017). This review will focus on challenging aspects of RSV vaccine development and aim to explore current vaccine approaches in clinical development to discuss which show potential for human vaccine viability.